Login Register Cart 0
Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

An Insight into Hepatitis C Virus: In Search of Promising Drug Targets

Author(s): Manish Dwivedi*, Aditya Dwivedi and Debalina Mukherjee

Volume 24, Issue 14, 2023

Published on: 27 October, 2023

Page: [1127 - 1138] Pages: 12

DOI: 10.2174/0113894501265769231020031857

Price: $65

Abstract

Hepatitis C Virus (HCV) is a global health concern, chronically infecting over 70 million people worldwide. HCV is a bloodborne pathogen that primarily affects the liver, and chronic HCV infection can lead to cirrhosis, liver cancer, and liver failure over time. There is an urgent need for more effective approaches to prevent and treat HCV. This review summarizes current knowledge on the virology, transmission, diagnosis, and management of HCV infection. It also provides an in-depth analysis of HCV proteins as promising targets for antiviral drug and vaccine development. Specific HCV proteins discussed as potential drug targets include the NS5B polymerase, NS3/4A protease, entry receptors like CD81, and core proteins. The implications of HCV proteins as diagnostic and prognostic biomarkers are also explored. Current direct-acting antiviral therapies are effective but have cost, genotype specificity, and resistance limitations. This review aims to synthesize essential information on HCV biology and pathogenesis to inform future research on improved preventive, diagnostic, and therapeutic strategies against this global infectious disease threat.

« Previous Next »
Graphical Abstract

[1]
McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology 2021; 73(S1): 4-13.
[http://dx.doi.org/10.1002/hep.31288]
[2]
Giuggioli D, Sebastiani M, Colaci M, et al. Treatment of HCV-related mixed cryoglobulinemia. Curr Drug Targets 2017; 18(7): 794-802.
[http://dx.doi.org/10.2174/1389450116666150825112105] [PMID: 26302805]
[3]
Wang Y, Jie W, Ling J, Yuanshuai H. HCV core antigen plays an important role in the fight against HCV as an alternative to HCV-RNA detection. J Clin Lab Anal 2021; 35(6): e23755.
[http://dx.doi.org/10.1002/jcla.23755] [PMID: 33788295]
[4]
Kessler HH, Stelzl E. Profile of Roche’s cobas® HCV tests. Expert Rev Mol Diagn 2017; 17(4): 311-9.
[http://dx.doi.org/10.1080/14737159.2017.1293526] [PMID: 28277143]
[5]
Lavie M, Goffard A, Dubuisson J. HCV glycoproteins: Assembly of a functional E1–E2 heterodimer. In: Tan SL, Ed. Hepatitis C Viruses: Genomes and Molecular Biology. Norfolk, UK: Horizon Bioscience 2006.
[6]
Zeisel MB, Felmlee DJ, Baumert TF. Hepatitis C virus entry. Curr Top Microbiol Immunol 2013; 369: 87-112.
[http://dx.doi.org/10.1007/978-3-642-27340-7_4] [PMID: 23463198]
[7]
Chan S, Ou J, Hepatitis C. Hepatitis C virus-induced autophagy and host innate immune response. Viruses 2017; 9(8): 224.
[http://dx.doi.org/10.3390/v9080224] [PMID: 28805674]
[8]
Kessler HH, Clarici AMK, Stelzl E, et al. Fully automated detection of hepatitis C virus RNA in serum and whole-blood samples. Clin Vaccine Immunol 2002; 9(6): 1385-8.
[http://dx.doi.org/10.1128/CDLI.9.6.1385-1388.2002] [PMID: 12414781]
[9]
Moradpour D, Penin F. Hepatitis C virus proteins: From structure to function. Curr Top Microbiol Immunol 2013; 369: 113-42.
[http://dx.doi.org/10.1007/978-3-642-27340-7_5] [PMID: 23463199]
[10]
Simmonds P. The origin of hepatitis C virus. Curr Top Microbiol Immunol 2013; 369: 1-15.
[http://dx.doi.org/10.1007/978-3-642-27340-7_1] [PMID: 23463195]
[11]
Wang L, James Ou J. Hepatitis C virus and autophagy. Biol Chem 2015; 396(11): 1215-22.
[http://dx.doi.org/10.1515/hsz-2015-0172] [PMID: 26024249]
[12]
Dubuisson J. Hepatitis C virus proteins. World J Gastroenterol 2007; 13(17): 2406-15.
[http://dx.doi.org/10.3748/wjg.v13.i17.2406] [PMID: 17552023]
[13]
Janot C, Botte C. Hepatitis C virus. Rev Fr Transfus Hemobiol 1992; 35(3): 155-62.
[http://dx.doi.org/10.1016/S1140-4639(05)80118-2]
[14]
Popescu CI, Rouillé Y, Dubuisson J. Hepatitis C virus assembly imaging. Viruses 2011; 3(11): 2238-54.
[http://dx.doi.org/10.3390/v3112238] [PMID: 22163343]
[15]
Pawlotsky JM. New hepatitis C therapies. Semin Liver Dis 2014; 34(1): 007-8.
[http://dx.doi.org/10.1055/s-0034-1371178] [PMID: 24782253]
[16]
Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G. Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 2014; 20(29): 9633-52.
[http://dx.doi.org/10.3748/wjg.v20.i29.9633] [PMID: 25110404]
[17]
Preciado MV, Valva P, Escobar-Gutierrez A, et al. Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy. World J Gastroenterol 2014; 20(43): 15992-6013.
[http://dx.doi.org/10.3748/wjg.v20.i43.15992] [PMID: 25473152]
[18]
Irshad M, Mankotia DS, Irshad K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol 2013; 19(44): 7896-909.
[http://dx.doi.org/10.3748/wjg.v19.i44.7896] [PMID: 24307784]
[19]
Osna NA, Thomes PG, Donohue TM Jr. Involvement of autophagy in alcoholic liver injury and hepatitis C pathogenesis. World J Gastroenterol 2011; 17(20): 2507-14.
[http://dx.doi.org/10.3748/wjg.v17.i20.2507] [PMID: 21633655]
[20]
Çetin Duran A, Kaya Çetinkaya O, Sayiner AA, Şeydaoğlu G, Özkarataş E, Abacıoğlu H. Changes on Hepatitis C virus genotype distribution in Western Turkey: Evaluation of twelve-year data. Turk J Gastroenterol 2020; 31(2): 128-35.
[http://dx.doi.org/10.5152/tjg.2020.18798] [PMID: 32141821]
[21]
Warkad SD, Nimse SB, Song KS, et al. Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples. Virol J 2018; 15(1): 107.
[http://dx.doi.org/10.1186/s12985-018-1017-4] [PMID: 29996859]
[22]
Fabrizi F, Tripodi F, Cerutti R, et al. Recent information on pan-genotypic direct-acting antiviral agents for hcv in chronic kidney disease. Viruses 2022; 14(11): 2570.
[http://dx.doi.org/10.3390/v14112570] [PMID: 36423179]
[23]
Chigbu D, Loonawat R, Sehgal M, Patel D, Jain P, Hepatitis C. Hepatitis C virus infection: Host–virus interaction and mechanisms of viral persistence. Cells 2019; 8(4): 376.
[http://dx.doi.org/10.3390/cells8040376] [PMID: 31027278]
[24]
Ma L, Li Q, Xie Y, et al. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro. Antiviral Res 2022; 207: 105419.
[http://dx.doi.org/10.1016/j.antiviral.2022.105419] [PMID: 36155070]
[25]
Gawlik K, Gallay PA. HCV core protein and virus assembly: What we know without structures. Immunol Res 2014; 60(1): 1-10.
[http://dx.doi.org/10.1007/s12026-014-8494-3] [PMID: 24557493]
[26]
Wang X, Zhou Y, Wang C, et al. HCV Core protein represses DKK3 expression via epigenetic silencing and activates the Wnt/β-catenin signaling pathway during the progression of HCC. Clin Transl Oncol 2022; 24(10): 1998-2009.
[http://dx.doi.org/10.1007/s12094-022-02859-y] [PMID: 35768685]
[27]
Grassi G, Di Caprio G, Fimia GM, Ippolito G, Tripodi M, Alonzi T. Hepatitis C virus relies on lipoproteins for its life cycle. World J Gastroenterol 2016; 22(6): 1953-65.
[http://dx.doi.org/10.3748/wjg.v22.i6.1953] [PMID: 26877603]
[28]
Suzuki T, Ishii K, Aizaki H, Wakita T. Hepatitis C viral life cycle. Adv Drug Deliv Rev 2007; 59(12): 1200-12.
[http://dx.doi.org/10.1016/j.addr.2007.04.014] [PMID: 17825945]
[29]
Romero-López C, Berzal-Herranz A. The Role of the RNA-RNA Interactome in the Hepatitis C Virus Life Cycle. Int J Mol Sci 2020; 21(4): 1479.
[http://dx.doi.org/10.3390/ijms21041479] [PMID: 32098260]
[30]
Colpitts CC, Lupberger J, Doerig C, Baumert TF. Host cell kinases and the hepatitis C virus life cycle. Biochim Biophys Acta Proteins Proteomics 2015; 1854(10): 1657-62.
[http://dx.doi.org/10.1016/j.bbapap.2015.04.011] [PMID: 25896387]
[31]
Rychłowska M, Bieńkowska-Szewczyk K. Hepatitis C--new developments in the studies of the viral life cycle. Acta Biochim Pol 2007; 54(4): 703-15.
[http://dx.doi.org/10.18388/abp.2007_3138] [PMID: 17957276]
[32]
Felmlee D, Hafirassou M, Lefevre M, Baumert T, Schuster C. Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses 2013; 5(5): 1292-324.
[http://dx.doi.org/10.3390/v5051292] [PMID: 23698400]
[33]
Dustin LB, Bartolini B, Capobianchi MR, Pistello M. Hepatitis C virus: Life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin Microbiol Infect 2016; 22(10): 826-32.
[http://dx.doi.org/10.1016/j.cmi.2016.08.025] [PMID: 27592089]
[34]
Dubuisson J, Cosset FL. Virology and cell biology of the hepatitis C virus life cycle – An update. J Hepatol 2014; 61(1): S3-S13.
[http://dx.doi.org/10.1016/j.jhep.2014.06.031] [PMID: 25443344]
[35]
Houghton M, Hepatitis C. Hepatitis C Virus: 30 Years after Its Discovery. Cold Spring Harb Perspect Med 2019; 9(12): a037069.
[http://dx.doi.org/10.1101/cshperspect.a037069] [PMID: 31501269]
[36]
Manns MP, Buti M, Gane E, et al. Hepatitis C virus infection. Nat Rev Dis Primers 2017; 3(1): 17006.
[http://dx.doi.org/10.1038/nrdp.2017.6] [PMID: 28252637]
[37]
Li HC, Yang CH, Lo SY. Cellular factors involved in the hepatitis C virus life cycle. World J Gastroenterol 2021; 27(28): 4555-81.
[http://dx.doi.org/10.3748/wjg.v27.i28.4555] [PMID: 34366623]
[38]
Li HC, Yang CH, Lo SY, Hepatitis C. Hepatitis C viral replication complex. Viruses 2021; 13(3): 520.
[http://dx.doi.org/10.3390/v13030520] [PMID: 33809897]
[39]
Ramírez S, Pérez-del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl 2008; 14(S2): S27-35.
[http://dx.doi.org/10.1002/lt.21644] [PMID: 18825723]
[40]
Rossi L, Escobar-Gutierrez A, Rahal P. Advanced molecular surveillance of hepatitis C virus. Viruses 2015; 7(3): 1153-88.
[http://dx.doi.org/10.3390/v7031153] [PMID: 25781918]
[41]
Lagging M, Wejstål R, Norkrans G, et al. Treatment of hepatitis C virus infection: Updated Swedish Guidelines 2016. Infect Dis 2017; 49(8): 561-75.
[http://dx.doi.org/10.1080/23744235.2017.1300682] [PMID: 28293974]
[42]
Booth JCL, Thomas HC. Pathogenesis of chronic hepatitis C and associated clinical manifestations. Baillieres Clin Gastroenterol 1996; 10(2): 257-74.
[http://dx.doi.org/10.1016/S0950-3528(96)90006-8] [PMID: 8864033]
[43]
Willems M, Moshage H, Fevery J, Yap SH, Hepatitis C. Hepatitis C. Neth J Med 1992; 41(1-2): 36-43.
[PMID: 1383840]
[44]
Chan A, Patel K, Naggie S. Genotype 3 infection: The last stand of hepatitis C Virus. Drugs 2017; 77(2): 131-44.
[http://dx.doi.org/10.1007/s40265-016-0685-x] [PMID: 28074358]
[45]
Campo DS, Zhang J, Ramachandran S, Khudyakov Y. Transmissibility of intra-host hepatitis C virus variants. BMC Genomics 2017; 18(S10): 881.
[http://dx.doi.org/10.1186/s12864-017-4267-4] [PMID: 29244001]
[46]
Régeard M, Lepère C, Trotard M, Gripon P, Le Seyec J. Recent contributions of in vitro models to our understanding of hepatitis C virus life cycle. FEBS J 2007; 274(18): 4705-18.
[http://dx.doi.org/10.1111/j.1742-4658.2007.06017.x] [PMID: 17824957]
[47]
Fukasawa M. Cellular lipid droplets and hepatitis C virus life cycle. Biol Pharm Bull 2010; 33(3): 355-9.
[http://dx.doi.org/10.1248/bpb.33.355] [PMID: 20190392]
[48]
González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterol 2016; 22(4): 1421-32.
[http://dx.doi.org/10.3748/wjg.v22.i4.1421] [PMID: 26819511]
[49]
Mukherjee R, Burns A, Rodden D, et al. Diagnosis and management of hepatitis C Virus infection. SLAS Technol 2015; 20(5): 519-38.
[http://dx.doi.org/10.1177/2211068214563794] [PMID: 25609256]
[50]
Simmonds P. Virology of hepatitis C virus. Clin Ther 1996; 18(-Suppl B): 9-36.
[http://dx.doi.org/10.1016/S0149-2918(96)80193-7]
[51]
Meier V, Ramadori G. Hepatitis C virus virology and new treatment targets. Expert Rev Anti Infect Ther 2009; 7(3): 329-50.
[http://dx.doi.org/10.1586/eri.09.12] [PMID: 19344246]
[52]
Moradpour D, Brass V, Gosert R, Wölk B, Blum HE. Hepatitis C: Molecular virology and antiviral targets. Trends Mol Med 2002; 8(10): 476-82.
[http://dx.doi.org/10.1016/S1471-4914(02)02395-X] [PMID: 12383770]
[53]
Chevaliez S, Pawlotsky JM. Hepatitis C virus: Virology, diagnosis and management of antiviral therapy. World J Gastroenterol 2007; 13(17): 2461-6.
[http://dx.doi.org/10.3748/wjg.v13.i17.2461] [PMID: 17552030]
[54]
Stuart JD, Salinas E, Grakoui A. Immune system control of hepatitis C virus infection. Curr Opin Virol 2021; 46: 36-44.
[http://dx.doi.org/10.1016/j.coviro.2020.10.002] [PMID: 33137689]
[55]
Werling K, Hunyady B, Makara M, et al. Hepatitis C screening and treatment program in hungarian prisons in the era of direct acting antiviral agents. Viruses 2022; 14(2): 308.
[http://dx.doi.org/10.3390/v14020308] [PMID: 35215901]
[56]
Crouchet E, Baumert TF, Schuster C. Hepatitis C virus–apolipoprotein interactions: Molecular mechanisms and clinical impact. Expert Rev Proteomics 2017; 14(7): 593-606.
[http://dx.doi.org/10.1080/14789450.2017.1344102] [PMID: 28625086]
[57]
Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol 2015; 21(2): 105-14.
[http://dx.doi.org/10.3350/cmh.2015.21.2.105] [PMID: 26157746]
[58]
Jackowiak P, Kuls K, Budzko L, Mania A, Figlerowicz M, Figlerowicz M. Phylogeny and molecular evolution of the hepatitis C virus. Infect Genet Evol 2014; 21: 67-82.
[http://dx.doi.org/10.1016/j.meegid.2013.10.021] [PMID: 24200590]
[59]
Alter MJ, Mast EE, Moyer LA, Margolis HS, Hepatitis C. Hepatitis C. Infect Dis Clin North Am 1998; 12(1): 13-26.
[http://dx.doi.org/10.1016/S0891-5520(05)70405-0] [PMID: 9494826]
[60]
Chalupa P, Holub M, Davidová A, Arientová S, Beran O. Immune response in the pathogenesis of hepatitis C virus infection. Epidemiol Mikrobiol Imunol 2015; 64(4): 198-203.
[61]
Koziel MJ. The role of immune responses in the pathogenesis of hepatitis C virus infection. J Viral Hepat 1997; 4(s2): 31-41.
[http://dx.doi.org/10.1111/j.1365-2893.1997.tb00178.x] [PMID: 9429208]
[62]
Forns X, Purcell RH, Bukh J. Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends Microbiol 1999; 7(10): 402-10.
[http://dx.doi.org/10.1016/S0966-842X(99)01590-5] [PMID: 10498948]
[63]
Bressanelli S, Tomei L, Roussel A, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA 1999; 96(23): 13034-9.
[http://dx.doi.org/10.1073/pnas.96.23.13034] [PMID: 10557268]
[64]
Polamreddy P, Vishwakarma V, Gundla R. a review on anti-hcv agents targeting active site and allosteric sites of non-structural protein 5b [NS5B]. Int J Pharm Pharm Sci 2016; 8(11): 1-18.
[http://dx.doi.org/10.22159/ijpps.2016v8i11.13965]
[65]
Taylor JG, Zipfel S, Ramey K, et al. Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®. Bioorg Med Chem Lett 2019; 29(16): 2428-36.
[http://dx.doi.org/10.1016/j.bmcl.2019.03.037] [PMID: 31133531]
[66]
Timm J, Roggendorf M. Sequence diversity of hepatitis C virus: Implications for immune control and therapy. World J Gastroenterol 2007; 13(36): 4808-17.
[http://dx.doi.org/10.3748/wjg.v13.i36.4808] [PMID: 17828811]
[67]
Krarup HB, Krogsgaard K. Hepatitis C. Ugeskr Laeger 1994; 156(28): 1429-34.
[68]
Li HC, Ma HC, Yang CH, Lo SY. Production and pathogenicity of hepatitis C virus core gene products. World J Gastroenterol 2014; 20(23): 7104-22.
[http://dx.doi.org/10.3748/wjg.v20.i23.7104] [PMID: 24966583]
[69]
Moradpour D, Cerny A, Heim MH, Blum HE. Hepatitis C: An update. Swiss Med Wkly 2001; 131(21-22): 291-8.
[http://dx.doi.org/10.4414/smw.2001.06097] [PMID: 11584690]
[70]
Dusheiko G, Simmonds P. Sequence variability of hepatitis C virus and its clinical relevance. J Viral Hepat 1994; 1(1): 3-15.
[http://dx.doi.org/10.1111/j.1365-2893.1994.tb00057.x] [PMID: 8790555]
[71]
Fauvelle C, Lepiller Q, Felmlee DJ, et al. Hepatitis C virus vaccines – Progress and perspectives. Microb Pathog 2013; 58: 66-72.
[http://dx.doi.org/10.1016/j.micpath.2013.02.005] [PMID: 23499591]
[72]
Weck K. Molecular methods of hepatitis C genotyping. Expert Rev Mol Diagn 2005; 5(4): 507-20.
[http://dx.doi.org/10.1586/14737159.5.4.507] [PMID: 16013969]
[73]
Zhou LY, Zhang LL. Host restriction factors for hepatitis C virus. World J Gastroenterol 2016; 22(4): 1477-86.
[http://dx.doi.org/10.3748/wjg.v22.i4.1477] [PMID: 26819515]
[74]
Ruggieri V, Mazzoccoli C, Pazienza V, Andriulli A, Capitanio N, Piccoli C. Hepatitis C virus, mitochondria and auto/mitophagy: Exploiting a host defense mechanism. World J Gastroenterol 2014; 20(10): 2624-33.
[http://dx.doi.org/10.3748/wjg.v20.i10.2624] [PMID: 24627598]
[75]
Esposito I, Trinks J, Soriano V. Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opin Drug Metab Toxicol 2016; 12(10): 1197-209.
[http://dx.doi.org/10.1080/17425255.2016.1209484] [PMID: 27384079]
[76]
Nolte FS. Laboratory diagnosis of hepatitis C. Immunol Invest 1997; 26(1-2): 199-207.
[http://dx.doi.org/10.3109/08820139709048927] [PMID: 9037624]
[77]
Du L, Tang H. An insight into the molecular characteristics of hepatitis C virus for clinicians. Saudi Med J 2016; 37(5): 483-91.
[http://dx.doi.org/10.15537/smj.2016.5.14178] [PMID: 27146609]
[78]
Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C. Zhonghua Gan Zang Bing Za Zhi 2019; 27(12): 962-79.
[http://dx.doi.org/10.3760/cma.j.issn.1007-3418.2019.12.008]
[79]
Seme K, Poljak M, Babič DZ, Močilnik T, Vince A. The role of core antigen detection in management of hepatitis C: A critical review. J Clin Virol 2005; 32(2): 92-101.
[http://dx.doi.org/10.1016/j.jcv.2004.10.005] [PMID: 15653411]
[80]
Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39(1): 5-19.
[http://dx.doi.org/10.1002/hep.20032] [PMID: 14752815]
[81]
Giannini C, Bréchot C. Hepatitis C virus biology. Cell Death Differ 2003; 10(S1): S27-38.
[http://dx.doi.org/10.1038/sj.cdd.4401121] [PMID: 12655344]
[82]
Gómez J, Martell M, Quer J, Cabot B, Esteban JI. Hepatitis C viral quasispecies. J Viral Hepat 1999; 6(1): 3-16.
[http://dx.doi.org/10.1046/j.1365-2893.1999.t01-1-6120131.x] [PMID: 10847126]
[83]
Budkowska A. Mechanism of cell infection with hepatitis C virus (HCV)--a new paradigm in virus-cell interaction. Pol J Microbiol 2009; 58(2): 93-8.
[PMID: 19824391]
[84]
Jo J, Lohmann V, Bartenschlager R, Thimme R. Experimental models to study the immunobiology of hepatitis C virus. J Gen Virol 2011; 92(3): 477-93.
[http://dx.doi.org/10.1099/vir.0.027987-0] [PMID: 21148278]
[85]
Ringelhan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci 1737; 372(1732): 20160274.
[http://dx.doi.org/10.1098/rstb.2016.0274]
[86]
Lim EJ, Torresi J. Prevention of hepatitis C virus infection and liver cancer. Recent Results Cancer Res 2014; 193: 113-33.
[http://dx.doi.org/10.1007/978-3-642-38965-8_7] [PMID: 24008296]
[87]
Nutini MFR, Hunter J, Giron L, et al. HCV genotype profile in Brazil of mono-infected and HIV co-infected individuals: A survey representative of an entire country. PLoS One 2020; 15(1): e0227082.
[http://dx.doi.org/10.1371/journal.pone.0227082] [PMID: 31905224]
[88]
Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61(1): 77-87.
[http://dx.doi.org/10.1002/hep.27259] [PMID: 25069599]
[89]
Sadler MD. Editorial: Genotype 3 HCV -who still needs ribavirin in a pan-genotypic era? Aliment Pharmacol Ther 2018; 47(11): 1548-9.
[http://dx.doi.org/10.1111/apt.14646] [PMID: 29878417]
[90]
Janiak M, Caraballo Cortés K, Perlejewski K, et al. Next-generation sequencing of Hepatitis C Virus (HCV) mixed-genotype infections in anti-HCV-negative blood donors. Adv Exp Med Biol 2018; 1096: 65-71.
[http://dx.doi.org/10.1007/5584_2018_190] [PMID: 29594753]
[91]
Wada N, Ikeda F, Mori C, et al. Mixed HCV infection of genotype 1B and other genotypes influences non-response during daclatasvir + asunaprevir combination therapy. Acta Med Okayama 2018; 72(4): 401-6.
[http://dx.doi.org/10.18926/AMO/56178] [PMID: 30140089]
[92]
Pawlotsky J-M, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018; 69(2): 461-511.
[http://dx.doi.org/10.1016/j.jhep.2018.03.026] [PMID: 29650333]
[93]
Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 2013; 57(2): 221-9.
[http://dx.doi.org/10.1093/cid/cit226] [PMID: 23575197]
[94]
Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016; 65(4): 727-33.
[http://dx.doi.org/10.1016/j.jhep.2016.06.015] [PMID: 27349488]
[95]
Amaddeo G, Nguyen CT, Maillé P, et al. Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy. Liver Int 2020; 40(1): 74-82.
[http://dx.doi.org/10.1111/liv.14226] [PMID: 31444947]
[96]
García-Ros A, Morán S, Núñez V, García-Ros G, Ruiz G, García-Solano J. Impact of direct-acting antiviral therapy on liver fibrosis regression among people with chronic HCV infection: Results from a real-life cohort in patients who achieved sustained virological response. Medicina 2023; 59(4): 814.
[http://dx.doi.org/10.3390/medicina59040814] [PMID: 37109770]
[97]
Raghuraman S, Abraham P, Sridharan G, Daniel HD, Ramakrishna BS, Shaji RV. HCV genotype 4—an emerging threat as a cause of chronic liver disease in Indian (south) patients. J Clin Virol 2004; 31(4): 253-8.
[http://dx.doi.org/10.1016/j.jcv.2004.03.019] [PMID: 15494265]
[98]
von Felden J, Vermehren J, Schulze zur Wiesch J, Sarrazin C, Christensen S. Editorial: Genotype 3 HCV -who still needs ribavirin in a pan-genotypic era? Authors’ reply. Aliment Pharmacol Ther 2018; 47(11): 1550-1.
[http://dx.doi.org/10.1111/apt.14648] [PMID: 29878436]
[99]
Qiu P, Stevens R, Wei B, et al. HCV genotyping from NGS short reads and its application in genotype detection from HCV mixed infected plasma. PLoS One 2015; 10(4): e0122082.
[http://dx.doi.org/10.1371/journal.pone.0122082] [PMID: 25830316]
[100]
Lapointe HR, Dong W, Dong WWY, et al. Validation of a genotype-independent hepatitis C virus near-whole genome sequencing assay. Viruses 2021; 13(9): 1721.
[http://dx.doi.org/10.3390/v13091721] [PMID: 34578305]
[101]
Peiffer KH, Kuhnhenn L, Stelzl E, et al. Performance of three common Hepatitis C Virus (HCV) genotyping assays for identification of HCV genotype 2/1 chimeras. J Clin Microbiol 2019; 57(7): e00060-19.
[http://dx.doi.org/10.1128/JCM.00060-19] [PMID: 31043467]
[102]
Zahid N, Ahmad R, Iqbal MS, Khan SA, Asghar SY, Shah MM. Detection of hepatitis through proteases and protease inhibitors genes expression and identification of HCV untypable genotype in Abbottabad, Pakistan. Acta Virol 2022; 65(4): 390-401.
[http://dx.doi.org/10.4149/av_2021_405] [PMID: 34796714]
[103]
Bouchardeau F, Cantaloube JF, Chevaliez S, et al. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 2007; 45(4): 1140-5.
[http://dx.doi.org/10.1128/JCM.01982-06] [PMID: 17251399]
[104]
Chao DT, Abe K, Nguyen MH. Systematic review: Epidemiology of hepatitis C genotype 6 and its management. Aliment Pharmacol Ther 2011; 34(3): 286-96.
[http://dx.doi.org/10.1111/j.1365-2036.2011.04714.x] [PMID: 21623850]
[105]
Bouacida L, Suin V, Hutse V, et al. Distribution of HCV genotypes in Belgium from 2008 to 2015. PLoS One 2018; 13(12): e0207584.
[http://dx.doi.org/10.1371/journal.pone.0207584] [PMID: 30517127]
[106]
Su R, Dong L, Wang Y, Sa R, Wang Y. Distribution of hepatitis C virus genotype and subtype between Mongolian and Han in Inner Mongolia. medicine 2022; 101(28): e29545.
[http://dx.doi.org/10.1097/MD.0000000000029545] [PMID: 35839017]
[107]
Sridhar S, Yip CCY, Chan JFW, To KKW, Cheng VCC, Yuen KY. Impact of inter-genotypic recombination and probe cross-reactivity on the performance of the Abbott RealTime HCV Genotype II assay for hepatitis C genotyping. Diagn Microbiol Infect Dis 2018; 91(1): 34-7.
[http://dx.doi.org/10.1016/j.diagmicrobio.2017.12.024] [PMID: 29434000]
[108]
Thong VD, Akkarathamrongsin S, Poovorawan K, Tangkijvanich P, Poovorawan Y. Hepatitis C virus genotype 6: Virology, epidemiology, genetic variation and clinical implication. World J Gastroenterol 2014; 20(11): 2927-40.
[http://dx.doi.org/10.3748/wjg.v20.i11.2927] [PMID: 24659883]
[109]
Vassilaki N, Mavromara P. The HCV ARFP/F/core+1 protein: Production and functional analysis of an unconventional viral product. IUBMB Life 2009; 61(7): 739-52.
[http://dx.doi.org/10.1002/iub.201] [PMID: 19548320]
[110]
Peña-Asensio J, Calvo H, Torralba M, Miquel J, Sanz-de-Villalobos E, Larrubia JR. Gamma-Chain Receptor Cytokines & PD-1 Manipulation to Restore HCV-Specific CD8+ T Cell Response during Chronic Hepatitis C. Cells 2021; 10(3): 538.
[http://dx.doi.org/10.3390/cells10030538] [PMID: 33802622]
[111]
Chalupa P, Holub M, Davidová A, Arientová S, Beran O. Imunitní odpověď v patogenezi infekce virem hepatitidy C. Epidemiol Mikrobiol Imunol 2015; 64(4): 198-203.
[PMID: 26795223]
[112]
Sengupta S, Parikh ND. Biomarker development for hepatocellular carcinoma early detection: Current and future perspectives. Hepat Oncol 2017; 4(4): 111-22.
[http://dx.doi.org/10.2217/hep-2017-0019] [PMID: 30191058]
[113]
Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53(3): 1020-2.
[http://dx.doi.org/10.1002/hep.24199] [PMID: 21374666]
[114]
Pan Y, Chen H, Yu J. Biomarkers in hepatocellular carcinoma: Current status and future perspectives. Biomedicines 2020; 8(12): 576.
[http://dx.doi.org/10.3390/biomedicines8120576] [PMID: 33297335]
[115]
Park SH, Bang CS, Kim DJ. Biomarkers in HCV infection. Adv Clin Chem 2015; 70: 131-96.
[http://dx.doi.org/10.1016/bs.acc.2015.03.001] [PMID: 26231487]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy